Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Capecitabine (Primary) ; Tosedostat (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Feb 2018 Planned End Date changed from 31 Mar 2019 to 9 Nov 2018.
- 04 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Jan 2018.
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.